NO324251B1 - <Beta>-karbolinderivater, farmasoytisk preparat inneholdende samme, fremgangsmate for fremstilling av farmasoytisk preparat ved anvendelse av beta-karbolinderivater for fremstilling av medikament - Google Patents

<Beta>-karbolinderivater, farmasoytisk preparat inneholdende samme, fremgangsmate for fremstilling av farmasoytisk preparat ved anvendelse av beta-karbolinderivater for fremstilling av medikament

Info

Publication number
NO324251B1
NO324251B1 NO20025527A NO20025527A NO324251B1 NO 324251 B1 NO324251 B1 NO 324251B1 NO 20025527 A NO20025527 A NO 20025527A NO 20025527 A NO20025527 A NO 20025527A NO 324251 B1 NO324251 B1 NO 324251B1
Authority
NO
Norway
Prior art keywords
preparation
beta
carboline derivatives
pharmaceutical preparation
drugs
Prior art date
Application number
NO20025527A
Other languages
English (en)
Norwegian (no)
Other versions
NO20025527L (no
NO20025527D0 (no
Inventor
Mark J Macielag
Zhihua Sui
Original Assignee
Ortho Mcneil Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Mcneil Pharm Inc filed Critical Ortho Mcneil Pharm Inc
Publication of NO20025527D0 publication Critical patent/NO20025527D0/no
Publication of NO20025527L publication Critical patent/NO20025527L/no
Publication of NO324251B1 publication Critical patent/NO324251B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
NO20025527A 2000-05-17 2002-11-18 <Beta>-karbolinderivater, farmasoytisk preparat inneholdende samme, fremgangsmate for fremstilling av farmasoytisk preparat ved anvendelse av beta-karbolinderivater for fremstilling av medikament NO324251B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20466700P 2000-05-17 2000-05-17
PCT/US2001/014357 WO2001087038A2 (fr) 2000-05-17 2001-05-03 Derives $g(b)-carboline utiles en tant qu'inhibiteurs de la phosphodiesterase

Publications (3)

Publication Number Publication Date
NO20025527D0 NO20025527D0 (no) 2002-11-18
NO20025527L NO20025527L (no) 2003-01-16
NO324251B1 true NO324251B1 (no) 2007-09-17

Family

ID=22758909

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20025527A NO324251B1 (no) 2000-05-17 2002-11-18 <Beta>-karbolinderivater, farmasoytisk preparat inneholdende samme, fremgangsmate for fremstilling av farmasoytisk preparat ved anvendelse av beta-karbolinderivater for fremstilling av medikament

Country Status (31)

Country Link
US (2) US6492358B2 (fr)
EP (1) EP1289985B1 (fr)
JP (1) JP5014551B2 (fr)
KR (1) KR20030031482A (fr)
CN (1) CN1255403C (fr)
AR (1) AR028576A1 (fr)
AT (1) ATE256127T1 (fr)
AU (2) AU2001261167B2 (fr)
BG (1) BG66141B1 (fr)
CA (1) CA2409715C (fr)
CZ (1) CZ20023934A3 (fr)
DE (1) DE60101479T2 (fr)
DK (1) DK1289985T3 (fr)
ES (1) ES2211806T3 (fr)
GE (1) GEP20053511B (fr)
HR (1) HRP20020910B1 (fr)
HU (1) HUP0302412A3 (fr)
IL (2) IL152873A0 (fr)
MX (1) MXPA02011426A (fr)
MY (1) MY128479A (fr)
NO (1) NO324251B1 (fr)
NZ (1) NZ522731A (fr)
PL (1) PL205507B1 (fr)
PT (1) PT1289985E (fr)
RU (1) RU2271358C2 (fr)
SK (1) SK16972002A3 (fr)
TR (1) TR200302309T4 (fr)
TW (1) TWI286553B (fr)
UA (1) UA74826C2 (fr)
WO (1) WO2001087038A2 (fr)
ZA (1) ZA200210111B (fr)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6987115B2 (en) * 2000-12-08 2006-01-17 Smithkline Beecham Corporation Antibacterial compounds
US6900220B2 (en) * 2001-01-02 2005-05-31 Syntex (U.S.A.) Llc Quinazolone derivatives as alpha 1A/B adrenergic receptor antagonists
ES2248412T3 (es) * 2001-02-12 2006-03-16 Lilly Icos Llc Derivados de carbolina.
ES2272695T3 (es) * 2001-02-12 2007-05-01 Lilly Icos Llc Derivados de carbolina.
EP1383765B1 (fr) * 2001-04-25 2006-12-13 Lilly Icos LLC Dérives de carboline en tant qu'inhibiteurs de phosphodiesterase 5 (PDE 5) pour le traitement des maladies cardiovasculaires et le dysfonctionnement érectile
EP1401835A1 (fr) * 2001-06-05 2004-03-31 Lilly Icos LLC Derives de carboline utilises comme inhibiteurs de pde-5
DE60213798T2 (de) * 2001-06-21 2007-08-16 Lilly Icos Llc, Wilmington Carbolinderivate als pdev inhibitoren
ES2289159T3 (es) 2001-11-14 2008-02-01 Ortho-Mcneil Pharmaceutical Corporation Derivados tetraciclicos sustituidos de pirroloquinolona utilizados como inhibidores de fosfodiesterasa.
CA2475108A1 (fr) * 2002-02-07 2003-08-14 Mitchell S. Steiner Traitement de l'hyperplasie prostatique benigne a l'aide de modulateurs selectifs des recepteurs androgenes (sarm)
DE60317684T4 (de) * 2002-06-19 2011-06-22 Janssen Pharmaceutica N.V., 2340 SUBSTITUIERTE 2,4-DIHYDROPYRROLOc3,4BÜCHINOLIN-9-ONDERIVATE, DIE SICH ALS PHOSPHODIESTERASEINHIBITOREN EIGNEN
US7872133B2 (en) * 2003-06-23 2011-01-18 Ono Pharmaceutical Co., Ltd. Tricyclic heterocycle compound
CN1910183A (zh) 2004-01-23 2007-02-07 希龙公司 四氢咔啉化合物作为抗癌药
US8076352B2 (en) 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Administration of carboline derivatives useful in the treatment of cancer and other diseases
US8076353B2 (en) 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Inhibition of VEGF translation
UA92317C2 (ru) 2004-03-15 2010-10-25 Пи-Ти-Си ТЕРАПЬЮТИКС, ИНК. Производные карболина, пригодные для ингибирования развития кровеносных сосудов
US7767689B2 (en) 2004-03-15 2010-08-03 Ptc Therapeutics, Inc. Carboline derivatives useful in the treatment of cancer
AR051780A1 (es) * 2004-11-29 2007-02-07 Japan Tobacco Inc Compuestos en anillo fusionados que contienen nitrogeno y utilizacion de los mismos
EP1829874B1 (fr) * 2004-12-22 2014-02-12 Ono Pharmaceutical Co., Ltd. Compose tricyclique et son utilisation
GB2422828A (en) * 2005-02-03 2006-08-09 Hunter Fleming Ltd Tricyclic cytoprotective compounds comprising an indole residue
AU2006275702A1 (en) * 2005-07-29 2007-02-08 Concert Pharmaceuticals Inc. Novel pharmaceutical compounds
EP2258358A3 (fr) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenèse avec un inhibiteur de l'acetylcholinestérase
EP2275095A3 (fr) 2005-08-26 2011-08-17 Braincells, Inc. Neurogenese par modulation des recepteurs muscariniques
EP1940389A2 (fr) 2005-10-21 2008-07-09 Braincells, Inc. Modulation de la neurogenese par inhibition de la pde
AU2006308889A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. GABA receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2382975A3 (fr) 2006-05-09 2012-02-29 Braincells, Inc. Neurogénèse par modulation d'angiotensine
JP2009536667A (ja) 2006-05-09 2009-10-15 ブレインセルス，インコーポレイティド ５ｈｔ受容体介在性の神経新生
AU2007292848A1 (en) * 2006-09-08 2008-03-13 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
EP2178537A4 (fr) * 2007-07-19 2011-08-17 Merck Sharp & Dohme Dérivés de bêta-carboline en tant que composés antidiabétiques
WO2009073534A2 (fr) 2007-11-30 2009-06-11 Maxthera Inc. Inhibiteurs de ppat bicycliques utilisés en tant qu'agents antibactériens
KR101614723B1 (ko) 2008-01-11 2016-04-22 알바니 몰레큘라 리써치, 인크. Ｍｃｈ 길항물질로서 (1-아지논)-치환된 피리도인돌
WO2009120717A2 (fr) 2008-03-24 2009-10-01 Medivation Technologies, Inc. Pyrido[3,4-b]indoles et leurs procédés d'utilisation
MD4009C2 (ro) * 2008-07-15 2010-08-31 Институт Химии Академии Наук Молдовы Utilizarea 1-metil-4-(N-metilaminobutil-4)-β-carbolinei în calitate de remediu antituberculos
WO2010099217A1 (fr) 2009-02-25 2010-09-02 Braincells, Inc. Modulation de neurogenèse à l'aide de combinaisons de d-cyclosérine
WO2010107485A1 (fr) * 2009-03-17 2010-09-23 The Trustees Of Columbia University In The City Of New York Inhibiteurs de ligase e3
US8618299B2 (en) 2009-07-01 2013-12-31 Albany Molecular Research, Inc. Azinone-substituted azapolycycle MCH-1 antagonists, methods of making, and use thereof
WO2011003007A1 (fr) 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Antagonistes de mch-1 d’azabicycloalcane-indole et d’azabicycloalcane-pyrrolo-pyridine, procédés de préparation, et utilisation de ceux-ci
JP2012532144A (ja) 2009-07-01 2012-12-13 アルバニー モレキュラー リサーチ， インコーポレイテッド アジノン置換アゼピノ［ｂ］インドールおよびピリド−ピロロ−アゼピンｍｃｈ−１拮抗薬、ならびにその作製方法および使用
US9073925B2 (en) 2009-07-01 2015-07-07 Albany Molecular Research, Inc. Azinone-substituted azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine MCH-1 antagonists, methods of making, and use thereof
CN102711467A (zh) * 2009-09-23 2012-10-03 梅迪维新技术公司 吡啶并[3,4-b]吲哚类及使用方法
ES2693247T3 (es) * 2010-07-06 2018-12-10 Ono Pharmaceutical Co., Ltd. Derivado de tetrahidrocarbolina
US8993765B2 (en) 2010-12-21 2015-03-31 Albany Molecular Research, Inc. Tetrahydro-azacarboline MCH-1 antagonists, methods of making, and uses thereof
US8697700B2 (en) 2010-12-21 2014-04-15 Albany Molecular Research, Inc. Piperazinone-substituted tetrahydro-carboline MCH-1 antagonists, methods of making, and uses thereof
WO2012127885A1 (fr) 2011-03-18 2012-09-27 小野薬品工業株式会社 Dérivé de tétrahydrocarboline
WO2013106547A1 (fr) 2012-01-10 2013-07-18 President And Fellows Of Harvard College Composés promoteurs de réplication des cellules bêta et leurs procédés d'utilisation
US10092574B2 (en) 2012-09-26 2018-10-09 Valorisation-Recherche, Limited Partnership Inhibitors of polynucleotide repeat-associated RNA foci and uses thereof
WO2017168174A1 (fr) 2016-04-02 2017-10-05 N4 Pharma Uk Limited Nouvelles formes pharmaceutiques du sildénafil
CN107216327A (zh) * 2017-06-27 2017-09-29 山东大学 5型磷酸二酯酶抑制剂及其制备方法和用途
US20220402914A1 (en) * 2019-09-03 2022-12-22 The Regents Of The University Of Colorado, A Body Corporate Tryptoline-Based Benzothiazoles and their use as Antibiotics and Antibiotic Resistance-Modifying Agents
EP4011877A3 (fr) * 2020-12-11 2023-01-11 Institut de Cardiologie de Montréal Méthodes de traitement du cholestérol plasmatique élevé
EP4267578A4 (fr) 2020-12-23 2024-11-20 Recurium IP Holdings, LLC Modulateurs du récepteur des éstrogènes
CN119462646A (zh) * 2024-11-07 2025-02-18 江苏科技大学 一种取代的四氢-β-咔啉衍生物、其合成方法及其用途

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1055203A (en) 1964-09-16 1967-01-18 Ici Ltd -ß-carboline derivatives, a process for their manufacture, and compositions containing them
US4228168A (en) 1978-11-22 1980-10-14 Tanabe Seiyaku Co., Ltd. Azepino [1,2,3-lm]-β-carboline compounds and pharmaceutical composition thereof
NZ194747A (en) 1979-08-29 1988-11-29 Schering Ag 9h-pyrido(3,4-b)indol-3-ylcarboxylic acid derivatives
WO1988002751A1 (fr) 1986-10-13 1988-04-21 Asahi Kasei Kogyo Kabushiki Kaisha Derives de pyridine
CS262100B1 (cs) * 1987-07-17 1989-02-10 Protiva Miroslav 1-substituované 2- [ (4-methyl-l-piperazinyl)acetyl ] -2,3,4,9- -tetrahydro-lH-pyrido( 3,4-b)indoly a jejich hydrochloridy
DE3855147D1 (de) 1987-07-20 1996-05-02 Duphar Int Res 8,9-Anellierte 1,2,3,4-Tetrahydro-beta-carbolin-Derivate
FR2619112B1 (fr) * 1987-08-07 1989-11-17 Synthelabo Derives de (piperidinyl-4)methyl-2 benzo(b)furo(2,3-c) pyridines, leur preparation et leur application en therapeutique
US4971974A (en) 1988-06-16 1990-11-20 Neurex Corporation Benzothiophenes as appetite suppressants
WO1990001483A1 (fr) 1988-08-11 1990-02-22 Asahi Kasei Kogyo Kabushiki Kaisha Derives de tetrahydropyridine
US5250534A (en) * 1990-06-20 1993-10-05 Pfizer Inc. Pyrazolopyrimidinone antianginal agents
FR2663935A1 (fr) 1990-06-27 1992-01-03 Adir Nouveaux 1,2,3,4,5,6-hexahydroazepino [4,5-b] indoles et 1,2,3,4-tetrahydrobethacarbolines, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.
GB9311920D0 (en) 1993-06-09 1993-07-28 Pfizer Ltd Therapeutic agents
GB9401090D0 (en) 1994-01-21 1994-03-16 Glaxo Lab Sa Chemical compounds
US5403851A (en) 1994-04-05 1995-04-04 Interneuron Pharmaceuticals, Inc. Substituted tryptamines, phenalkylamines and related compounds
DE69531476T2 (de) * 1994-09-12 2004-06-09 Lilly Industries Ltd., Basingstoke Serotonergische Modulatoren
FR2724384B1 (fr) 1994-09-14 1999-04-16 Cemaf Nouveaux derives de la 3,4-dihydro beta-carboline agonistes de la melatonine, leur procede de preparation et leur utilisation a titre de medicament
DE4436190A1 (de) 1994-10-10 1996-04-11 Gerhard Prof Dr Bringmann Halogenierte ß-Carbolin-Derivate, Verfahren zu ihrer Herstellung und Verwendung dieser Substanzen zur Hemmung der Atmungskette
DE4436509A1 (de) 1994-10-13 1996-04-18 Hoechst Schering Agrevo Gmbh Substituierte Spiroalkylamino- und alkoxy-Heterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Schädlingsbekämpfungsmittel und Fungizide
GB9423911D0 (en) 1994-11-26 1995-01-11 Pfizer Ltd Therapeutic agents
GB9423910D0 (en) 1994-11-26 1995-01-11 Pfizer Ltd Therapeutic agents
US5968910A (en) * 1994-11-30 1999-10-19 Jan M. R. Balzarini Compositions containing two or three inhibitors of different HIV reverse transcriptases
GB9514464D0 (en) 1995-07-14 1995-09-13 Glaxo Lab Sa Medicaments
FR2748026B1 (fr) 1996-04-26 1998-06-05 Adir Nouveaux inhibiteurs de metalloproteases, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
BR9709230A (pt) 1996-05-10 1999-08-10 Icos Corp Composto
EP0985671B1 (fr) 1996-05-31 2003-04-02 Mochida Pharmaceutical Co., Ltd. DERIVES DE PYRIDOCARBAZOLE AYANT UN EFFET INHIBITEUR DE cGMP-PDE
EP0973778A1 (fr) 1997-03-07 2000-01-26 Novo Nordisk A/S DERIVES DE 4,5,6,7-TETRAHYDRO-THIENO 3,2-c]PYRIDINE, LEUR PREPARATION ET LEUR UTILISATION
US6043252A (en) 1997-05-05 2000-03-28 Icos Corporation Carboline derivatives
WO2000002878A1 (fr) 1998-07-11 2000-01-20 University Of Bristol Composes possedant une activite sur les recepteurs d'imidazoline
FR2796644B1 (fr) * 1999-07-23 2001-09-07 Adir Nouveaux derives de beta-carboline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
MXPA02011426A (es) 2004-09-06
WO2001087038A3 (fr) 2002-05-16
DK1289985T3 (da) 2004-04-05
ZA200210111B (en) 2004-03-12
NZ522731A (en) 2004-09-24
PL205507B1 (pl) 2010-04-30
US6492358B2 (en) 2002-12-10
IL152873A (en) 2012-01-31
UA74826C2 (en) 2006-02-15
HK1051368A1 (en) 2003-08-01
SK16972002A3 (sk) 2003-11-04
CN1255403C (zh) 2006-05-10
US6864253B2 (en) 2005-03-08
NO20025527L (no) 2003-01-16
IL152873A0 (en) 2003-06-24
ATE256127T1 (de) 2003-12-15
MY128479A (en) 2007-02-28
GEP20053511B (en) 2005-05-10
DE60101479T2 (de) 2005-04-28
AR028576A1 (es) 2003-05-14
BG66141B1 (bg) 2011-07-29
CZ20023934A3 (cs) 2003-10-15
HRP20020910A2 (en) 2004-12-31
CN1446217A (zh) 2003-10-01
CA2409715C (fr) 2010-09-14
RU2271358C2 (ru) 2006-03-10
BG107285A (bg) 2003-07-31
US20020010189A1 (en) 2002-01-24
US20030166641A1 (en) 2003-09-04
AU2001261167B2 (en) 2006-10-05
JP5014551B2 (ja) 2012-08-29
AU6116701A (en) 2001-11-26
HRP20020910B1 (hr) 2011-02-28
TWI286553B (en) 2007-09-11
NO20025527D0 (no) 2002-11-18
HUP0302412A2 (hu) 2003-11-28
EP1289985A2 (fr) 2003-03-12
CA2409715A1 (fr) 2001-11-22
PL365445A1 (en) 2005-01-10
KR20030031482A (ko) 2003-04-21
EP1289985B1 (fr) 2003-12-10
HUP0302412A3 (en) 2007-02-28
ES2211806T3 (es) 2004-07-16
TR200302309T4 (tr) 2004-02-23
PT1289985E (pt) 2004-03-31
DE60101479D1 (en) 2004-01-22
JP2003533453A (ja) 2003-11-11
WO2001087038A2 (fr) 2001-11-22

Similar Documents

Publication Publication Date Title
NO324251B1 (no) &lt;Beta&gt;-karbolinderivater, farmasoytisk preparat inneholdende samme, fremgangsmate for fremstilling av farmasoytisk preparat ved anvendelse av beta-karbolinderivater for fremstilling av medikament
EE200100431A (et) 16-halogenoepotilooni derivaadid, nende valmistamismeetod ja farmatseutiline kasutamine
NO20032734D0 (no) Nye 1,2-difenylazetidinonderivater, fremgangsmåte for deres fremstilling, legemidler som inneholder nevnte forbindelser og anvendelse avdisse for behandling av sykdommer fra lipidstoffskiftet
HUP0203142A3 (en) Benzodiazepine derivatives, process for preparation of the compounds, pharmaceutical compositions containing them and their use
EE200100684A (et) Indalüülasendatud benseenkarboksamiidid, nende valmistamismeetod, kasutamine ja farmatseutilised kompositsioonid
HUP0204226A3 (en) Quinazoline derivatives, pharmaceutical compositions containing them, their use and process for the preparation of the compounds
NO20031692D0 (no) Fremgangsmåte for fremstilling av pulverformuleringer
EE200200017A (et) Kinuklidiinderivaadid, nende valmistamismeetod, vaheühendid, farmatseutiline kompositsioon ja nendekasutamine
HUP0300157A3 (en) Anti-inflammatory and analgesic heterocyclo-alkylsulfonyl pyrazole derivatives, process for their preparation and pharmaceutical compounds containing them
HUP0401747A3 (en) Piridazine derivatives of hydrazono-malonitriles, their use, process for preparation of the compounds and pharmaceutical compositions containing the compounds
NO20014738L (no) Tolperisonholdig farmasöytisk preparat for oral administrering
HUP0202075A3 (en) Substituted 2-dialkylaminoalkylbiphenyl derivatives, process for their preparation, pharmaceutical compositions containing them and their use
DE60301570D1 (de) 1,2,3-substituierte indolizinderivate, fgf inhibitoren, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen
HUP0301075A3 (en) Diphenyl ether derivatives, their use for preparation of pharmaceutical compositions and process for preparation the compounds
AU2002341241A1 (en) Process for the preparation of fast dissolving dosage form
NO326689B1 (no) Pyrrolidinderivater, anvendelse derav, farmasøytisk preparat samt fremgangsmåte for fremstilling av forbindelsene
EE200100711A (et) Naftüridiini derivaadid, nende valmistamismeetod ning neid sisaldav farmatseutiline kompositsioon
EE04683B1 (et) A-grupi streptogramiinide derivaadid, nende valmistamismeetod ja farmatseutiline kompositsioon
HUP0400317A3 (en) Beta-carboline derivatives, process for their preparation, their use and pharmaceutical compositions containing them
EE200200252A (et) Antikehade kasutamine vaktsiinidena, antikehi sisaldavad farmatseutilised kompositsioonid, meetod antikehapreparaadi valmistamiseks ja meetod farmatseutilise kompositsiooni valmistamiseks
NO20005000D0 (no) FremgangsmÕte for fremstilling av rÕstoffer for glassfremstilling
NO20021368L (no) Fremgangsmåte for fremstilling av fenyleddiksyre derivater
HUP0301784A3 (en) Biphenyl derivatives, of imidazole and benzimidazole the use thereof, process for the preparation of compounds and pharmaceutical compositions containing them
NO20004638D0 (no) Hypnotisk &lt;beta&gt;-karbolinderivater, fremgangsmÕte til deres fremstilling og deres anvendelse som legemiddelprodukt
NO20012518L (no) Fremgangsmåte ved fremstilling av legemidler i fast administrasjonsform

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees